$17.16
Insights on Guardant Health, Inc.
Revenue is up for the last 8 quarters, 96.09M → 155.05M (in $), with an average increase of 6.6% per quarter
Netprofit is down for the last 3 quarters, -72.77M → -187.04M (in $), with an average decrease of 67.8% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 26.8% return, outperforming this stock by 40.4%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 3.2% return, outperforming this stock by 92.3%
1.22%
Downside
Day's Volatility :5.09%
Upside
3.92%
7.87%
Downside
52 Weeks Volatility :61.5%
Upside
58.21%
Period | Guardant Health, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -21.65% | 1.1% | 0.0% |
6 Months | -29.21% | 12.5% | 0.0% |
1 Year | -13.56% | 6.9% | 2.2% |
3 Years | -89.08% | 14.3% | -23.0% |
Market Capitalization | 2.1B |
Book Value | $1.31 |
Earnings Per Share (EPS) | -4.28 |
Wall Street Target Price | 39.06 |
Profit Margin | -85.02% |
Operating Margin TTM | -73.42% |
Return On Assets TTM | -17.64% |
Return On Equity TTM | -438.13% |
Revenue TTM | 563.9M |
Revenue Per Share TTM | 5.04 |
Quarterly Revenue Growth YOY | 22.2% |
Gross Profit TTM | 293.2M |
EBITDA | -436.3M |
Diluted Eps TTM | -4.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.17 |
EPS Estimate Next Year | -2.86 |
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Next Quarter | -0.87 |
What analysts predicted
Upside of 127.62%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 90.6M | ↑ 81.85% |
Net Income | -85.1M | ↑ 2.21% |
Net Profit Margin | -93.85% | ↑ 73.12% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 214.4M | ↑ 136.52% |
Net Income | -67.9M | ↓ 20.23% |
Net Profit Margin | -31.65% | ↑ 62.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 286.7M | ↑ 33.75% |
Net Income | -246.3M | ↑ 262.98% |
Net Profit Margin | -85.89% | ↓ 54.24% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 373.7M | ↑ 30.32% |
Net Income | -384.8M | ↑ 56.23% |
Net Profit Margin | -102.98% | ↓ 17.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 449.5M | ↑ 20.31% |
Net Income | -654.6M | ↑ 70.12% |
Net Profit Margin | -145.61% | ↓ 42.63% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 563.9M | ↑ 25.45% |
Net Income | -479.4M | ↓ 26.76% |
Net Profit Margin | -85.02% | ↑ 60.59% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 117.4M | ↑ 7.57% |
Net Income | -162.0M | ↓ 29.39% |
Net Profit Margin | -137.98% | ↑ 72.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 126.9M | ↑ 8.08% |
Net Income | -139.9M | ↓ 13.62% |
Net Profit Margin | -110.28% | ↑ 27.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 128.7M | ↑ 1.44% |
Net Income | -133.5M | ↓ 4.57% |
Net Profit Margin | -103.74% | ↑ 6.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 137.2M | ↑ 6.55% |
Net Income | -72.8M | ↓ 45.5% |
Net Profit Margin | -53.06% | ↑ 50.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 143.0M | ↑ 4.29% |
Net Income | -86.1M | ↑ 18.32% |
Net Profit Margin | -60.2% | ↓ 7.14% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 155.1M | ↑ 8.41% |
Net Income | -187.0M | ↑ 117.23% |
Net Profit Margin | -120.63% | ↓ 60.43% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 587.4M | ↑ 71.29% |
Total Liabilities | 62.5M | ↑ 81.9% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 962.5M | ↑ 63.86% |
Total Liabilities | 114.5M | ↑ 83.41% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 136.02% |
Total Liabilities | 916.2M | ↑ 699.87% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↓ 2.96% |
Total Liabilities | 1.6B | ↑ 70.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 26.97% |
Total Liabilities | 1.5B | ↓ 0.62% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 10.96% |
Total Liabilities | 1.6B | ↑ 5.03% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 8.2% |
Total Liabilities | 1.5B | ↑ 0.03% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↓ 5.39% |
Total Liabilities | 1.5B | ↑ 0.96% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 6.11% |
Total Liabilities | 1.6B | ↑ 0.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 21.72% |
Total Liabilities | 1.5B | ↓ 0.57% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.33% |
Total Liabilities | 1.6B | ↑ 1.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 0.6% |
Total Liabilities | 1.6B | ↑ 3.75% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -72.2M | ↓ 0.07% |
Investing Cash Flow | -153.0M | ↓ 10.2% |
Financing Cash Flow | 293.2M | ↑ 4.08% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.1M | ↓ 34.7% |
Investing Cash Flow | -317.6M | ↑ 107.52% |
Financing Cash Flow | 367.3M | ↑ 25.29% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -103.9M | ↑ 120.49% |
Investing Cash Flow | -617.1M | ↑ 94.31% |
Financing Cash Flow | 1.4B | ↑ 283.96% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -209.0M | ↑ 101.12% |
Investing Cash Flow | -63.2M | ↓ 89.77% |
Financing Cash Flow | -66.8M | ↓ 104.74% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -309.5M | ↑ 48.06% |
Investing Cash Flow | 149.8M | ↓ 337.22% |
Financing Cash Flow | -189.1M | ↑ 182.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -78.2M | ↓ 30.17% |
Investing Cash Flow | 41.3M | ↓ 156.62% |
Financing Cash Flow | -19.3M | ↓ 88.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -90.7M | ↑ 16.11% |
Investing Cash Flow | 70.6M | ↑ 71.12% |
Financing Cash Flow | 2.3M | ↓ 112.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -74.4M | ↓ 17.97% |
Investing Cash Flow | 157.2M | ↑ 122.61% |
Financing Cash Flow | -854.0K | ↓ 136.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -94.0M | ↑ 26.29% |
Investing Cash Flow | -241.1M | ↓ 253.37% |
Financing Cash Flow | 383.9M | ↓ 45047.78% |
Sell
Neutral
Buy
Guardant Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Guardant Health, Inc. | 5.66% | -29.21% | -13.56% | -89.08% | -72.32% |
Idexx Laboratories, Inc. | -6.69% | 24.36% | 2.66% | -11.49% | 112.61% |
Agilent Technologies Inc. | -4.79% | 31.81% | 3.28% | 0.11% | 77.59% |
Thermo Fisher Scientific, Inc. | 0.67% | 33.29% | 5.29% | 16.87% | 114.21% |
Danaher Corp. | 0.78% | 29.98% | 7.72% | -2.98% | 91.25% |
Iqvia Holdings Inc. | -2.79% | 32.9% | 26.77% | 3.18% | 73.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Guardant Health, Inc. | NA | NA | NA | -3.17 | -4.38 | -0.18 | NA | 1.31 |
Idexx Laboratories, Inc. | 49.04 | 49.04 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.3 | 33.3 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.17 | 37.17 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 46.53 | 46.53 | 3.13 | 7.15 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.69 | 32.69 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Guardant Health, Inc. | Buy | $2.1B | -72.32% | NA | -85.02% |
Idexx Laboratories, Inc. | Buy | $41.0B | 112.61% | 49.04 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 77.59% | 33.3 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $219.3B | 114.21% | 37.17 | 13.99% |
Danaher Corp. | Buy | $187.5B | 91.25% | 46.53 | 18.55% |
Iqvia Holdings Inc. | Buy | $43.4B | 73.64% | 32.69 | 9.06% |
Vanguard Group Inc
BlackRock Inc
Baillie Gifford & Co Limited.
FMR Inc
Deep Track Capital, LP
Capital Research & Mgmt Co - Division 3
Guardant Health, Inc.’s price-to-earnings ratio stands at None
Read Morewe believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
Organization | Guardant Health, Inc. |
Employees | 1768 |
CEO | Dr. Helmy Eltoukhy Ph.D. |
Industry | Health Services |
Cerevel Therapeutics Holdings Inc
$17.16
-5.19%
Vaxcyte Inc
$17.16
-5.19%
Janux Therapeutics Inc
$17.16
-5.19%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$17.16
-5.19%
Radnet Inc
$17.16
-5.19%
The St. Joe Co
$17.16
-5.19%
Harley-davidson, Inc.
$17.16
-5.19%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$17.16
-5.19%
Aurora Innovation Inc
$17.16
-5.19%